Emerging COVID‐19 vaccines: A rheumatology perspective

Byravan, Swetha; Fardanesh, Armin; Tahir, Hasan; Moorthy, Arumugam

doi:10.1111/1756-185x.14048

Cited by 3 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sufficient information about vaccine effectiveness and safety in the immunosuppressed is warranted. Patients are willing and concerned to receive the COVID-19 vaccine, hence, rheumatologists should be prepared with the proper information before counseling their patients [20].…”

Section: Discussionmentioning

confidence: 99%

“…Google Trends analysis has shown that throughout the pandemic the interest in a coronavirus vaccine and anti-vaccine searches has increased and peaks are found when breakthroughs are announced [39]. The relationship between vaccination uptake and perception is complex [20]. The main resistance foreseen with some of the rheumatology patients in taking the vaccine is likely to be their perception rather than scientific reasoning [20].…”

Section: Discussionmentioning

confidence: 99%

“…The relationship between vaccination uptake and perception is complex [20]. The main resistance foreseen with some of the rheumatology patients in taking the vaccine is likely to be their perception rather than scientific reasoning [20]. In Turkey, the low rate of vaccine acceptance among patients with RD, as well as general population sampling is worrying according to a web-based survey.…”

Section: Discussionmentioning

confidence: 99%

“…Apart from live vaccines, all other vaccines are currently safe to use for RD patients and build-up a sufficient response to provide immunity. This creates an optimistic outlook for the new COVID-19 vaccine and its anticipated therapeutic effect [20]. Some evidence indicates that immunosuppressive therapy inhibits humoral response to the influenza, and pneumococcal vaccines.…”

Section: Discussionmentioning

confidence: 99%

“…Emergence of several potential vaccines has been the topic of discussion, also in Egypt. Most proposed COVID-19 vaccines are two dose regimens, and the second dose will hopefully cover those patients who did not produce a strong immune response with the first dose [20]. Whilst the safety and efficacy of the vaccines are mostly reassuring, reports of unfavorable immunological reactions to the vaccine may be of primary concern to patients with autoimmune diseases with limited information [3].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Rheumatology university faculty opinion on coronavirus disease-19 (COVID-19) vaccines: the vaXurvey study from Egypt

et al. 2021

View full text Add to dashboard Cite

Objectives The aim of the present work was to explore the perspectives of Egyptian Rheumatology staff members as regards the coronavirus disease-19 (COVID-19) vaccine. Methods The survey is composed of 25 questions. Some questions were adapted from the global rheumatology alliance COVID-19 survey for patients. Results 187 rheumatology staff members across Egypt from 18 universities and authorizations actively participated with a valid response. The mean time needed to complete the survey was 17.7 ± 13 min. Participants were 159 (85%) females (F:M 5.7:1). One-third agreed that they will be vaccinated once available, 24.6% have already received at least one dose, 29.4% are unsure while 16% will not take it. Furthermore, 70.1% agreed that they will recommend it to the rheumatic diseases (RD) patients once available, 24.1% are not sure while 5.9% will not recommend it. RD priority to be vaccinated against COVID-19 in descending order include SLE (82.9%), RA (55.1%), vasculitis (51.3%), systemic sclerosis (39.6%), MCTD (31.6%), Behcet's disease (28.3%). The most common drugs to be avoided before vaccination included biologics (71.7%), DMARDs (44.4%), biosimilars (26.7%), IVIg (17.1%) and NSAIDs (9.1%). Conclusions The results of the study and specifically the low rate of acceptability are alarming to Egyptian health authorities and should stir further interventions to reduce the levels of vaccine hesitancy. As rheumatic disease patients in Egypt were not systematically provided with the vaccine till present, making the vaccine available could as well enhance vaccine acceptance. Further studies to investigate any possible side effects, on a large scale of RD patients are warranted.

show abstract

Section: Discussionmentioning

confidence: 99%